Literature DB >> 23553686

A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome.

O Picone1, C Vauloup-Fellous, A G Cordier, S Guitton, M V Senat, F Fuchs, J M Ayoubi, L Grangeot Keros, A Benachi.   

Abstract

OBJECTIVE: To analyze the outcome of maternal primary cytomegalovirus (CMV) infection.
METHODS: Retrospective analysis of a cohort of 238 patients with maternal primary CMV infection detected at routine screening. The cases were managed with serial ultrasound (US) scans, and amniocentesis was performed in 36.1% of cases. All prenatal results were confirmed at birth.
RESULTS: The average age was 31.9 (18-44) years. Patients were symptomatic in 21% of cases. The rate of intrauterine transmission was 24.9%, and it was 8.8%, 19%, 30.6%, 34.1% and 40% in the preconceptional period, the periconceptional period, and the first, second and third trimesters of pregnancy, respectively (p = 0.025). There was a significantly higher risk of US abnormalities when maternal infection occurred during the preconceptional or periconceptional period and the first trimester compared with later (p < 0.001). Because of US abnormalities, pregnancy was terminated in 18 cases at the parents' request. Three infected newborns were symptomatic; all three cases were suspected at US before birth. We did not observe any symptomatic fetal infection when maternal infection occurred after 14 weeks of gestation. A number of clinically asymptomatic cases (5.5%) developed hearing loss.
CONCLUSION: The rate of materno fetal transmission is linearly correlated to the gestational age at infection. No severe case of congenital infection was observed if maternal infection occurred after 14 weeks of gestation.
© 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23553686     DOI: 10.1002/pd.4118

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  38 in total

1.  The unique immunological and microbial aspects of pregnancy.

Authors:  Gil Mor; Paulomi Aldo; Ayesha B Alvero
Journal:  Nat Rev Immunol       Date:  2017-06-19       Impact factor: 53.106

2.  Clinical Diagnostic Testing for Human Cytomegalovirus Infections.

Authors:  Raymund R Razonable; Naoki Inoue; Swetha G Pinninti; Suresh B Boppana; Tiziana Lazzarotto; Liliana Gabrielli; Giuliana Simonazzi; Philip E Pellett; D Scott Schmid
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 3.  Viral infections during pregnancy.

Authors:  Michelle Silasi; Ingrid Cardenas; Ja-Young Kwon; Karen Racicot; Paula Aldo; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2015-01-13       Impact factor: 3.886

Review 4.  Primary Human Cytomegalovirus (HCMV) Infection in Pregnancy.

Authors:  Horst Buxmann; Klaus Hamprecht; Matthias Meyer-Wittkopf; Klaus Friese
Journal:  Dtsch Arztebl Int       Date:  2017-01-27       Impact factor: 5.594

5.  In Reply.

Authors:  H Buxmann; K Hamprecht
Journal:  Dtsch Arztebl Int       Date:  2017-07-24       Impact factor: 5.594

Review 6.  Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity.

Authors:  William J Britt
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

7.  Importance of diagnostic work-up of Guillain-Barré syndrome in pregnancy.

Authors:  Elza Pollak-Christian; Kyong-Soon Lee
Journal:  BMJ Case Rep       Date:  2016-12-01

Review 8.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

9.  Cytomegalovirus Infection in Pregnancy - Counselling Challenges in the Setting of Generalised Testing.

Authors:  Anca Maria Ciobanu; Nicolae Gica; Corina Gica; Radu Botezatu; Mirona Furtuna; Gheorghe Peltecu; Anca Maria Panaitescu
Journal:  Maedica (Bucur)       Date:  2020-06

10.  The role of maternal screening in diagnosing congenital cytomegalovirus infections in highly immune populations.

Authors:  F Şahiner; M Honca; Y Çekmez; A Kubar; T Honca; M K Fidanci; T Purtuloğlu; M Yapar
Journal:  Ir J Med Sci       Date:  2014-06-04       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.